An Extension Study of EV-BR1701 Part A1
Long-Term Immunogenicity Study of an Adjuvanted Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children: An Extension Study of EV-BR1701 Part A1
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
I. Study Design:
EV-BR1701 was a randomized, multi-nation, multi-centered, double-blinded, phase III study to evaluate the efficacy and safety of an EV71 vaccine, EnVAX-A71, in healthy infants and children in Taiwan (Part A) and Vietnam (Part B). In both Parts, a sub-study for immunogenicity assessment for up to one year was performed. This extension study of EV-BR1701 aims to evaluate the long-term immunogenicity persistence more than 5 years after EnVAX-A71 vaccination in subjects originally participating in the immunogenicity sub-study in Taiwan.
The evaluable subjects of EV-BR1701 Part A1(immunogenicity sub-study), who were aged 2 months to < 6 years when entering the main study and completed two injections of either EnVAX-A71 or placebo with evaluable data for the primary immunogenicity endpoint, will be recalled to enter this extension study for phlebotomy and immunogenicity analysis. These subjects will not receive further vaccination according to this extension study protocol.
The principal investigators (PIs) and study coordinators (SCs) of the original medical center will contact the subject's guardians/legal representative by phone to return to the medical center for phlebotomy. Informed consent will be provided to the guardian/legal representative of the subjects, and the eligibility of subjects will be verified on the day of the recall visit.
After the subject is evaluated by the PI and meets the phlebotomy requirements, the subject's guardian/legal representative will be asked to sign the informed consent form, and the subject will be given the same identifier as what he/she was originally assigned in the main study for continuity of his/her immunogenicity data.
About 3-4 mL of blood will be collected from each subject, and the serum will be collected and sent to the designated central laboratory for testing. The validated neutralizing antibody (NTAb) analysis method will be used to determine the EV71-specific neutralizing antibody titer. The NTAb titer results will be directly sent to the CRO Data Management Team, and statistical analysis for immunogenicity will be performed and reported.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Hsinchu, Taiwan
- National Taiwan University Hospital HsinChu Branch
-
Taichung, Taiwan
- China Medical University Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taoyuan, Taiwan
- Linkou Chang Gung Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Healthy children who were enrolled in Part A1 (immunogenicity sub-study) of EV-BR1701, received two injections of either EnVAX-A71 or placebo, and had blood sample collected on Day 56 for primary immunogenicity endpoint analysis (the "evaluable" subjects).
- The subject's guardian/legal representative is able and willing to comply with study procedures and provide signed informed consent.
Exclusion Criteria:
- History of bleeding disorder, hemostatic difficulties or significant bruising caused by phlebotomy since the last visit in EV-BR1701 main study.
- Having been vaccinated with any EV71 vaccine products.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The long-term immunogenicity of EnVAX-A71 on the seroconversion rate (SCR)
Lasso di tempo: From Sep-2025 to Dec-2025
|
SCR (seroconversion rate) is defined as the percentage of subjects achieving either a pre-vaccination neutralizing antibody titer <1:8 and a post-vaccination neutralizing antibody titer ≥1:32, OR a pre-vaccination neutralizing antibody titer ≥1:8 and a minimum 4-fold increase in post-vaccination neutralizing antibody titer.
|
From Sep-2025 to Dec-2025
|
|
The long-term immunogenicity of EnVAX-A71 on SPR
Lasso di tempo: From Sep-2025 to Dec-2025
|
SPR (seroprotection rate, the proportion of the subjects with NTAb against EV71 titer ≥1:32)
|
From Sep-2025 to Dec-2025
|
|
The long-term immunogenicity of EnVAX-A71 on the geometric mean titer (GMT) and geometric mean titer ratio (GMTR) of EV71 neutralizing antibody (NTAb)
Lasso di tempo: From Sep-2025 to Dec-2025
|
GMTR (geometric mean titer ratio) is defined as the GMT at the recall visit divided by the GMT at pre-vaccination (Day 0 of main study).
|
From Sep-2025 to Dec-2025
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Wendy Wu, Enimmune Corporation
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EV-BR1701 Part A1 Extension
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da enterovirus
-
Medigen Vaccine Biologics Corp.Completato
-
Beijing Chaoyang District Centre for Disease Control...Sconosciuto
-
Medigen Vaccine Biologics Corp.CompletatoEnterovirus 71 umanoTaiwan
-
Medigen Vaccine Biologics Corp.CompletatoInfezione da Enterovirus 71Taiwan, Vietnam
-
Shandong Province Centers for Disease Control and...Hunan Provincial Center for Disease Control and Prevention; Shaanxi Provincial...SconosciutoEnterovirus 71 vaccino inattivato | HFMDCina
-
China Medical University HospitalSconosciutoEnterovirus 71, genetica dell'ospite, fattori sociali, comportamentali, ambientali
-
Sinovac Biotech Co., LtdCompletatoInfezione; Virale, EnterovirusCina
-
Medigen Vaccine Biologics Corp.Attivo, non reclutante
-
Bayi Children's Hospital Affiliated to PLA Army...SconosciutoInfezione da Enterovirus durante il periodo perinataleCina
-
University Hospital, Clermont-FerrandLaboratory of virology, National Enterovirus and parechovirus Reference Center...Sconosciuto